These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25831801)

  • 21. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.
    Lacouture ME
    Cancer Nurs; 2007; 30(4 Suppl 1):S17-26. PubMed ID: 17666987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
    Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
    Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): a new tool for grading and managing skin adverse reactions to epidermal growth factor receptor inhibitors.
    Lisi P; Bellini V; Bianchi L
    Oncology; 2014; 87(5):311-9. PubMed ID: 25196815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Side effects of targeted therapies. Introduction.
    Eaby-Sandy B
    Semin Oncol Nurs; 2014 Aug; 30(3):137-8. PubMed ID: 25085024
    [No Abstract]   [Full Text] [Related]  

  • 25. [Dermatological reactions in patients in antineoplastic therapy].
    Prasad SC; Vestergaard H; Bygum A
    Ugeskr Laeger; 2014 May; 176(11):. PubMed ID: 25096844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Are targeted therapies better tolerated?].
    Stiefelhagen P
    MMW Fortschr Med; 2015 Apr; 157(7):23-4. PubMed ID: 26012443
    [No Abstract]   [Full Text] [Related]  

  • 27. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
    Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
    Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
    Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
    Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapies in oncology come of age.
    Klein A
    Clin Ther; 2013 Sep; 35(9):1256-7. PubMed ID: 24054702
    [No Abstract]   [Full Text] [Related]  

  • 31. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
    Hu JC; Sadeghi P; Pinter-Brown LC; Yashar S; Chiu MW
    J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
    Lacouture ME; Basti S; Patel J; Benson A
    J Support Oncol; 2006 May; 4(5):236-8. PubMed ID: 16724647
    [No Abstract]   [Full Text] [Related]  

  • 33. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.
    Chen AP; Setser A; Anadkat MJ; Cotliar J; Olsen EA; Garden BC; Lacouture ME
    J Am Acad Dermatol; 2012 Nov; 67(5):1025-39. PubMed ID: 22502948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New drugs in oncology: benefits, risks and challenges].
    Cella D; Vervölgyi V; Wörmann B
    Onkologie; 2013; 36 Suppl 5():12-9. PubMed ID: 23921801
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
    Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
    Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dermocosmetology as a support for targeted oncologic treatment].
    Piérard-Franchimont C; Lesuisse M; Piérard GE
    Rev Med Liege; 2014 Jan; 69(1):35-7. PubMed ID: 24640306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor.
    Campanati A; Berardi R; Onofri A; Pierantoni C; Conte I; Giuliodori K; Molinelli E; Marcucci F; Cascinu S; Offidani A
    Ann Oncol; 2012 Apr; 23(4):1081-2. PubMed ID: 22457259
    [No Abstract]   [Full Text] [Related]  

  • 38. [Management of adverse effects of targeted therapy toxicities in oncology].
    Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
    Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skin toxicities of targeted therapies.
    Segaert S; Chiritescu G; Lemmens L; Dumon K; Van Cutsem E; Tejpar S
    Eur J Cancer; 2009 Sep; 45 Suppl 1():295-308. PubMed ID: 19775626
    [No Abstract]   [Full Text] [Related]  

  • 40. Dermatologic toxicities of targeted anticancer therapies.
    Balagula Y; Lacouture ME; Cotliar JA
    J Support Oncol; 2010; 8(4):149-61. PubMed ID: 20822032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.